CFM
CTKB icon

Catalyst Funds Management’s Cytek Biosciences CTKB Stock Holding History

Catalyst Funds Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+62,500
New +$267K 0.02% 513
2024
Q3 		– Sell
-2,700
Closed -$15.1K – 1358
2024
Q2 		$15.1K Buy
2,700
+2,400
+800% +$14.4K ﹤0.01% 778
2024
Q1 		$2.01K Buy
+300
New +$2.37K ﹤0.01% 1052

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Catalyst Funds Management's CTKB Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 62,500 shares worth $277K. The stake represents 0.02% of the portfolio and ranks #513 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in CTKB as recently as Q2 2024.

Catalyst Funds Management first reported a position in CTKB in Q1 2024 and has held it in 3 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Catalyst Funds Management held 62,500 shares of Cytek Biosciences worth $277K as of Q2 2026.
  • Cytek Biosciences was a new Catalyst Funds Management position in Q2 2026.
  • Cytek Biosciences made up 0.02% of Catalyst Funds Management's portfolio in Q2 2026, its #513 holding.
  • Catalyst Funds Management first reported a position in Cytek Biosciences in Q1 2024 and has held it in 3 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.